This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

AboutUnmet NeedCommunity-acquired PneumoniaComplicated Skin & Soft Tissue InfectionsMode of ActionVideoCommunity-acquired PneumoniaComplicated Skin & Soft Tissue InfectionsPatient ProfilesProfiles of Patients With CAPIdentify ZINFORO® Patient With CAPProfiles of Patients With cSSTIIdentify ZINFORO® Patient With cSSTIDosingRecommended Dosing ScheduleSimple DosingRenal AdjustmentEfficacyCommunity-acquired PneumoniaClinical Efficacy: Proven Clinical EfficacyClinical Efficacy: Evidence of Rapid ResponsePivotal Clinical StudiesMicrobiology: Optimising OutcomesMicrobiology: CoverageMicrobiology: Low MIC ValuesComplicated Skin & Soft Tissue InfectionsClinical Efficacy: Proven Clinical EfficacyClinical Efficacy: Evidence of Rapid ResponsePivotal Clinical StudiesMicrobiology: Optimising OutcomesMicrobiology: CoverageMicrobiology: Low MIC ValuesSafetySafetyKey safety featuresLow Incidence of Discontinuation in CAPLow Incidence of Discontinuation in cSSTIClinical & Scientific Data Clinical & Scientific Data Efficacy in the Treatment of CAPClinical Cure Rates Against Relevant PathogensClinical Cure Rates Across Patient SubgroupsDemonstrated Superiority to CeftriaxoneEarly Clinical ResponseReal-world Efficacy in Elderly PatientsConsistent Clinical Cure Rates in cSSTIClinical Cure Rates in Common Causative PathogensClinical Cure Rates in Patients With ComorbiditiesEarly Clinical EfficacyReal-life Efficacy in Clinical PracticeSupport & ResourcesSupport & ResourcesClinical updatesPrescribing InformationVideosWebinars

Clinical Updates

In vitro activity in patients with skin infections1
 

Ceftaroline was active against the gram-positive isolates collected. Susceptibility of ESBL-negative gram-negative isolates showed regional variations.1

​​​​​​​​​​​​​​​​​​​​​PP-ZFO-IND-0225

 

Click to view​​​​​
Loading


Ceftaroline achieved PTAs for bacteriostatic and bactericidal targets2
 

Ceftaroline achieved PTAs >99.9% for bacteriostatic and bactericidal targets at the MIC90 (1 mg/L), whereas the comparators failed to achieve PTAs >90% for bacteriostatic or bactericidal targets, even when clinical doses were increased beyond the recommended level(s).2
​​​​​​​
​​​​​​​​​​​​​​PP-ZFO-IND-0249
​​​​​​

Click to view​​​​​
Loading


Exploratory analyses of the Phase 3 COVERS trial3
 

Ceftaroline fosamil is a beta-lactam antibiotic with in vitro activity against MRSA. The Phase 3 COVERS study demonstrated the efficacy and safety of a high-dose regimen of ceftaroline fosamil (600 mg 2-hour IV infusions q8h) versus vancomycin plus aztreonam in hospitalised patients with cSSTI and underlying comorbidities.3

​​​​​​​PP-ZFO-IND-0254

LoadingClick to view​​​​​
Loading

Ceftaroline fosamil showed high efficacy/effectiveness in patients with any type of pneumonia with a good safety profile4
 

Pneumonia is a relevant clinical and public health issue worldwide frequently associated with infections caused by MDR pathogens. On the basis of this analysis, ceftaroline fosamil showed high efficacy/effectiveness in patients with any type of pneumonia with a good safety profile.4
​​​​​​​
​​​​​​​PP-ZFO-IND-0250

LoadingClick to view​​​​​
Loading


A real-world 2-centre experience in Italy and Spain5
 

Ceftaroline is one of the latest additions to the armamentarium for treating CAP. Considering its spectrum of activity, ceftaroline could represent an important therapeutic option for SCAP.5
​​​​​​​
​​​​​​​​​​​​​​PP-ZFO-IND-0251

LoadingClick to view​​​​​
Loading
Header
Header Header Header
Content Content Content
Content Content Content
Content Content Content
Content Content Content
Content Content Content
Content Content Content
Content Content Content
Content Content Content

​​​​​

CAP, community-acquired pneumonia; COVERS, CeftarOline versus Vancomycin and aztrEonam tReating cSSTI; cSSTI, complicated skin and soft tissue infection; ESBL, extended-spectrum beta-lactamase; ICU, intensive care unit; IV, intravenous; MDR, multidrug resistant; MIC90, minimum inhibitory concentration at which 90% of the isolates are inhibited; MRSA, methicillin-resistant Staphylococcus aureus; PTA, probability of target attainment; q8h; every 8 hours; SCAP, severe community-acquired pneumonia.

References:

Piérard D, Stone GG. In vitro activity of ceftaroline and comparators against bacterial isolates collected globally from patients with skin infections. J Glob Antimicrob Resist. 2021;26:4-10.​​​​​​​Cristinacce A, Wright JG, Macpherson M, Iaconis J, Das S. Comparing probability of target attainment against Staphylococcus aureus for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models. Diagn Microbiol Infect Dis. 2021;99(suppl 4):115292.Sánchez-García M, Hammond J, Yan JL, et al. Baseline characteristics and outcomes among patients with complicated skin and soft tissue infections admitted to the intensive care unit: analysis of the phase 3 COVERS randomized trial of ceftaroline fosamil versus vancomycin plus aztreonam. Infect Dis Ther. 2020;9(suppl 3):609-623.Sotgiu G, Aliberti S, Gramegna A, et al. Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis. Respir Res. 2018;19(suppl 1):205.Bassetti M, Russo A, Cilloniz C, et al. Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain. Int J Antimicrob Agents. 2020;55(suppl 4):105921.
Support & resources
About

Fifth-generation cephalosporin with broad coverage

Learn more


Efficacy

Proven clinical efficacy in patients with
CAP and cSSTI

Review efficacy profile


Dosing

Simple dosing with a flexible infusion time

Learn moreLoading


Safety

Safety profile consistent with other cephalosporins

Review safety profile


Clinical & Scientific Data

​​​​ZINFORO® in the treatment of CAP and cSSTI​​​​​​

Learn more



​​​​​Please click the Prescribing Information link to view the safety and adverse events information of ZINFORO®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
​​​​​​​
PP-ZFO-IND-0417 June 2022

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-ZFO-IND-0417

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 14 July 2022
Yes No
You are now leaving PfizerPro website

​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
​PP-UNP-IND-0012 14 July 2022